News

They have a knack for increasing their dividends even when facing challenges.

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-

With Amulet 360, Abbott aims to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to lower stroke risk.

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

His AbbVie purchase was a big move into a high-yielding dividend stock.

Three catalysts, one reshuffling, and a Fed that refuses to move

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

These two high-quality dividend payers have had very different fortunes recently.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

On August 11, medtech leader Abbott Laboratories (NYSE:ABT) and tech behemoth Alphabet Inc. (NASDAQ:GOOG) announced a multi-year partnership to unite continuous glucose monitoring with consumer AI. The collaboration embeds data from Abbott’s non-prescription Lingo biowearable directly into the Google Health app, combining real-time metabolic insights with Google’s AI Health Coach to deliver personalized habit recommendations […]

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder return is down 17.86%. This points to...

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. Health and biotech stocks are acting well in the current market. Several biotech and health names can be found on the IBD 50 list of top growth stocks.

These companies' recent headwinds shouldn't lead to decreased payouts.

AbbVie still looks like a compelling buy at its all-time high.

July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its ‌diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.

July 29 (Reuters) - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed ​